Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA
- PMID: 15778705
- DOI: 10.1038/nbt1081
Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA
Abstract
Short interfering RNAs (siRNAs) that mediate specific gene silencing through RNA interference (RNAi) are widely used to study gene function and are also being developed for therapeutic applications. Many nucleic acids, including double- (dsRNA) and single-stranded RNA (ssRNA), can stimulate innate cytokine responses in mammals. Despite this, few studies have questioned whether siRNA may have a similar effect on the immune system. This could significantly influence the in vivo application of siRNA owing to off-target effects and toxicities associated with immune stimulation. Here we report that synthetic siRNAs formulated in nonviral delivery vehicles can be potent inducers of interferons and inflammatory cytokines both in vivo in mice and in vitro in human blood. The immunostimulatory activity of formulated siRNAs and the associated toxicities are dependent on the nucleotide sequence. We have identified putative immunostimulatory motifs that have allowed the design of siRNAs that can mediate RNAi but induce minimal immune activation.
Similar articles
-
Induction of inflammatory cytokines and interferon responses by double-stranded and single-stranded siRNAs is sequence-dependent and requires endosomal localization.J Mol Biol. 2005 May 20;348(5):1079-90. doi: 10.1016/j.jmb.2005.03.013. Epub 2005 Mar 22. J Mol Biol. 2005. PMID: 15854645
-
Design of noninflammatory synthetic siRNA mediating potent gene silencing in vivo.Mol Ther. 2006 Mar;13(3):494-505. doi: 10.1016/j.ymthe.2005.11.002. Epub 2005 Dec 15. Mol Ther. 2006. PMID: 16343994
-
Sequence-specific potent induction of IFN-alpha by short interfering RNA in plasmacytoid dendritic cells through TLR7.Nat Med. 2005 Mar;11(3):263-70. doi: 10.1038/nm1191. Epub 2005 Feb 20. Nat Med. 2005. PMID: 15723075
-
RNA interference and innate immunity.Adv Drug Deliv Rev. 2007 Mar 30;59(2-3):153-63. doi: 10.1016/j.addr.2007.03.006. Epub 2007 Mar 16. Adv Drug Deliv Rev. 2007. PMID: 17459518 Review.
-
Gene silencing through RNA interference (RNAi) in vivo: strategies based on the direct application of siRNAs.J Biotechnol. 2006 Jun 25;124(1):12-25. doi: 10.1016/j.jbiotec.2005.12.003. Epub 2006 Jan 18. J Biotechnol. 2006. PMID: 16413079 Review.
Cited by
-
Asymmetric siRNA: new strategy to improve specificity and reduce off-target gene expression.Hum Gene Ther. 2012 May;23(5):521-32. doi: 10.1089/hum.2011.145. Epub 2012 Mar 9. Hum Gene Ther. 2012. PMID: 22229698 Free PMC article.
-
Modulation of the RNA Interference Activity Using Central Mismatched siRNAs and Acyclic Threoninol Nucleic Acids (aTNA) Units.Molecules. 2015 Apr 24;20(5):7602-19. doi: 10.3390/molecules20057602. Molecules. 2015. PMID: 25919280 Free PMC article.
-
Recent advances in siRNA delivery mediated by lipid-based nanoparticles.Adv Drug Deliv Rev. 2020;154-155:64-78. doi: 10.1016/j.addr.2020.07.022. Epub 2020 Aug 6. Adv Drug Deliv Rev. 2020. PMID: 32768564 Free PMC article. Review.
-
Exploring the Impact of mRNA Modifications on Translation Efficiency and Immune Tolerance to Self-Antigens.Vaccines (Basel). 2024 Jun 5;12(6):624. doi: 10.3390/vaccines12060624. Vaccines (Basel). 2024. PMID: 38932353 Free PMC article.
-
Adenosine modification may be preferred for reducing siRNA immune stimulation.Nucleic Acid Ther. 2012 Jun;22(3):205-10. doi: 10.1089/nat.2011.0334. Epub 2012 Apr 20. Nucleic Acid Ther. 2012. PMID: 22519815 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources